Heartflow (HTFL) Q4 2025 earnings review
Record Margins Clouded by Looming Growth Deceleration
Heartflow capped off a milestone FY25 with Q4 revenues surging 40% YoY to $49.1M, driven by strong U.S. FFR CT volumes. The standout achievement is profitability at the unit level: AI-driven efficiencies propelled gross margins to 79.5%, up 450 basis points from last year. Furthermore, the company shed its historical financial baggage by eliminating debt and fully resolving its volatile common stock warrants. However, beneath this 'record year' narrative lies a glaring concern: FY26 guidance projects revenue growth will decelerate sharply to ~25%. While the balance sheet is pristine ($280M in cash), the path to operating profitability remains obscured by heavy R&D and SG&A investments.
🐂 Bull Case
Gross margins are accelerating. Heartflow hit 79.5% in Q4 (up from 75.0% YoY) and is guiding for 80-81% next year. AI efficiency initiatives are successfully decoupling revenue growth from production costs.
The massive non-cash warrant liability charges ($43.9M in FY25) and debt extinguishment costs are gone. FY26 earnings will finally reflect actual operating performance without severe below-the-line noise.
🐻 Bear Case
Despite management's claim of 'accelerating adoption,' FY26 revenue guidance of $218-$222M implies a steep deceleration to 24-26% YoY growth, down from the 40% growth achieved in both Q4 and the full FY25.
Total operating expenses continue to scale alongside revenue, remaining stubbornly high at 116% of total revenue in Q4. Adjusted EBITDA showed minimal improvement, printing -$11.1M in Q4 compared to -$12.0M a year ago.
⚖️ Verdict: ⚪
Neutral. The transition to 80%+ gross margins and a clean balance sheet is highly attractive, but the unexpected drop in FY26 top-line growth guidance forces a re-evaluation of Heartflow's near-term market penetration speed.
Key Themes
AI Efficiencies Driving Margin Acceleration
Gross margin is accelerating rapidly, jumping from 75.0% in 24Q4 to 79.5% in 25Q4, and guiding to 80-81% for FY26. Management explicitly linked this expansion to improved production team productivity driven by proprietary AI efficiency initiatives. This validates the thesis that Heartflow can scale its 160 million annotated CTA image database to reduce human-in-the-loop costs.
Growth Deceleration Contradicts Management Optimism
Management noted their 'conviction in the business has never been higher' based on 'accelerating adoption.' However, the data contradicts this narrative: FY26 revenue guidance mid-point of $220M represents 25% YoY growth. This is a severe deceleration from the 40% growth delivered in both Q4 and the full FY25. This suggests the core U.S. FFR CT market may be encountering penetration friction or extended sales cycles.
Macro Reimbursement Environment Rapidly Opening
Aetna commenced coverage for Heartflow Plaque Analysis in Q4, joining UnitedHealthcare and Cigna (who initiated in Q3). This brings total U.S. covered lives for Plaque to approximately 75%. This broad macro-level reimbursement tailwind effectively removes the primary financial barrier for hospital adoption and sets a strong foundation for the Plaque product to contribute to FY26.
Operating Expense Creep
Despite massive gross margin improvements, net operating loss expanded YoY from -$16.1M to -$17.8M in Q4. Operating expenses consumed 116% of revenue in Q4, driven by aggressive hiring in sales and R&D. The company is failing to show meaningful operating leverage at the bottom line despite a 40% surge in top-line sales.
Balance Sheet Cleanse Complete
Heartflow enters FY26 with a radically transformed financial structure. Following the Q3 IPO and debt payoff, Q4 saw the complete net exercise of all common stock warrants. This ends the era of highly volatile, stock-price-triggered non-cash charges ($43.9M in FY25) destroying GAAP net income.
International Growth Lagging U.S. Expansion
While U.S. revenues grew an impressive 41% YoY to $44.8M in Q4, International revenues grew at a slower 35% clip to $4.3M. For the full year, international grew only 26%. The ex-U.S. market represents less than 10% of total revenue and is failing to act as a secondary growth engine.
Other KPIs
Stable. Showed marginal improvement from -$12.0M in 24Q4, and a slight dip from -$9.8M in 25Q3. The company is holding burn relatively steady while top-line scales, but the timeline to breakeven remains extended.
Extremely healthy liquidity position following the August IPO. With an Adjusted EBITDA burn rate of roughly $45M per year, Heartflow has well over 5 years of runway, eliminating any near-term dilution risks.
Represents 33% penetration into the total U.S. installed base of 1,465 accounts. With 75% of covered lives now active, closing the gap between the total base and the Plaque base will be a critical FY26 driver.
Guidance
Decelerating. The implied 24% to 26% YoY growth marks a significant slowdown from FY25's 40% growth. This is the primary red flag in the report, indicating that base effects are catching up to the company's core FFR CT product.
Accelerating. Upward trajectory continues from FY25's 77.0%. This cements Heartflow's profile as a high-margin software/AI business rather than a traditional medical device company.
Key Questions
Revenue Deceleration Drivers
FY26 guidance models a drop from 40% to ~25% growth. How much of this deceleration is due to U.S. FFR CT market saturation versus elongated sales cycles for new accounts?
Path to Profitability
With gross margins crossing 80%, what specific revenue threshold or timeline is management targeting for Adjusted EBITDA breakeven, given that OpEx continues to grow in tandem with sales?
Plaque Analysis Monetization
Now that Aetna has initiated coverage (securing ~75% of U.S. covered lives), what percentage of the guided FY26 revenue growth is expected to come directly from Plaque Analysis upsells versus core FFR CT volume?
International Strategy
International revenue growth (26% for FY25) is trailing U.S. growth significantly. What structural or reimbursement barriers are preventing faster adoption in European and Asian markets?